Hicks, Rodney J.

Delivering affordable cancer care in high-income countries

Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology

Economic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life

Cited by 718

Somatostatin Receptor Imaging with 68 Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

Hofman, M. S., Lau, W. F. E., & Hicks, R. J. (2015) · RadioGraphics

Neuroendocrine Tumor Research AdvancesMedical Imaging Techniques and Applications

Cited by 561

Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

Cited by 504

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., et al. (2012) · Clinical Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 415

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S.-T., et al. (2022) · The Lancet Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 296

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177 Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 292

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Thang, S. P., Violet, J., Sandhu, S., Iravani, A., Akhurst, T., Kong, G., Ravi Kumar, A., Murphy, D. G., Williams, S. G., Hicks, R. J., et al. (2019) · European Urology Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 183

Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions

Fanti, S., Minozzi, S., Morigi, J. J., Giesel, F., Ceci, F., Uprimny, C., Hofman, M. S., Eiber, M., Schwarzenbock, S., Castellucci, P., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging

Prostate Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications

Cited by 113

Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients

Quak, E., Le Roux, P.-Y., Hofman, M. S., Robin, P., Bourhis, D., Callahan, J., Binns, D., Desmonts, C., Salaun, P.-Y., Hicks, R. J., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging

Medical Imaging Techniques and ApplicationsCardiac Imaging and Diagnostics

Cited by 107